secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2022-09-16T23:59:59+00:00
Accession:  0001193125-22-246494
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 5.03, 2.03, 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FLAG shareholders approve extension to Dec 14; 18.9M shares redeemed, co-CEO appointed
--------------------------------------------------------------------------------

- Stockholders approved extension of business combination deadline to Dec 14, 2022, with three additional 3-month extensions possible.
- Redemption of 18,871,976 shares, leaving 4,128,024 shares outstanding; trust account now $41.6M.
- Issued extension notes totaling $490,000 to sponsor and Metric to fund extension and working capital.
- Appointed Thomas A. Vecchiolla as co-CEO alongside William J. Weber, effective Sept 15, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000119312522246494/0001193125-22-246494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000119312522246494/d361604d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-246494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer